Selected Recent Publications

Nisman, B., Barak, V., Shapiro, A., Golijanin, D., Peretz, T.,  Pode, D. Evaluation of Urine CYFRA 21-1 for the Detection of Primary and Recurrent Bladder Cancer. Cancer. 94,2914-2922, 2002.

R. Einarsson and Barak V. TPS: A Cytokeratin serum Tumor Marker for effective therapy control of cancer patients with focus on breast cancer. J. Clinical Ligand Assay. 22(4), 348-352, 2000.

Barak V. Cytokeratins as tumor markers.  J. Tumor Marker Oncology. 15(3), 3-4, 2000.

Nisman B., Heching N. and Barak V.  Serum tumor markers in resectable and non-resectable non-small cell lung cancer. J. Tumor Marker Oncology. 15(3), 11-23, 2000.

Barak V.,  Nisman B., Hubert A., Lyass O., Kaduri L., Peretz T. Prognostic efficacy of TPS in breast cancer. J. Tumor Marker Oncology. 15(3), 4-10, 2000

Nisman, B., Amir, G., Lafair, J., Heshing, J., Liass, O., Peretz, T.and Barak, V.,:  Prognostic value of TPS, Cyfra 21-1 and CEA in different histologic types of non-small cell lung cancer. Anticancer research.19(5):3549-3552,1999.

Barak, V., Nisman, B., Polliack, A.:TNF family in hairy cell leukemia - correlation to disease activity and prognosis.  Eur. J. of Hematol. 62:71-75, 1999.

Barak., V.,  Nisman, B., Kalichman, I., Farbstein, H, Baider, L., Stephanos, S., Kaplan, A. and Peretz, T.  Changes in cytokine production of breast cancer patients treated with Interferons. Cytokine. 10(12) 977-983, 1998.

Nagler, A., Bishara, A., Brautbar, C., and Barak, V.:   Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.  Cytokines, Cellular and Molecular Therapy. 4:161-167, 1998..

Nisman, B., Lafair, J., Heshing, J., Lyass, O., Peretz, T. and Barak, V.,: Evaluation of TPS, Cyfra 21-1 and CEA in non-small cell lung cancer: does the combined use of cytokeratin markers give any additional information? Cancer. 82:1850-1859, 1998.

Barak, V., Nisman, B., Polliack, A., Vannier, E., and Dinarello, C.A.: Circulating levels of IL-1 family members in Hairy Cell Leukemia: correlation with disease activity and response to treatment. Eur. Cytokine Netw. 9(1):33-39, 1998.

Van Dalen, A., Barak, V., Cremaschi, A., Gion, M., Molina, R., Namer, M., Stieber, P., Sturgeon, C., Einarsson, R. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. The Int. J. Biol. Markers. 13(1):10-15, 1998.

Nisman, B., Barak, V., Heching, N., Kramer, M., Reinus, C., Lafair,J. Cytokeratin markers in Malignant Pleural Mesothelioma. Cancer Det. Prevent. 22(5):416-422, 1998.

Nisman, B., Lafair, J., Lyass, O., Dranitzki-Elhalel, M. and Barak, V.:  Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J. Tumor Marker Oncology. 13(2):33-40, 1998.

Barak, V., Schwartz, A., Kalickman, I., Nisman, B., Gurman, G., Shoenfeld, Y:

Hypophosphatemia as a diagnostic tool in sepsis: the role of cytokines. Am. J. of Medicine. 104:40-47, 1998.

Barak, V., Nisman, B.,Roisman, I.,Hubert, A.,Farbstein, H.,Baider, L.,Kaplan, A., Halperin, T., Stephanos, S., Peretz, T.:  TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons.  J. Tumor Marker Oncology. 12(4):17-26, 1997.

Peretz, T., Kaplan Denour, A., Baider, L., Hubert, A., Stephanos, S. and Barak,V.: The combination of Interferon and Tamoxifen for patients with advanced breast cancer and negative estrogen receptors.  The Breast. 6(4):190-193, 1997.

Van Dalen, A., Heering, K.J. (Gouda), Barak, V., Peretz, T.(Jerusalem), Cremaschi, A., Geroni, P. (Romano di Lombardia), Gion, M., Saracchini, S. (Venice), Molina, R. (Barcelona), Namer, N. (Nice), Stieber, P.(Munich), Sturgeon C., Leonard, R.C.F. (Edinburgh), Einarsson, R. (Stockholm):  Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker    changes. The Breast. 5:82-88, 1996.

Barak, V, , Livni, N.,  Peretz, T., Libson, Y., Manny, J., Durst, A.L.and Roisman, I.: The role of  CA 15-3 expression in serum and tissue of breast cancer patients.  J. Tumor. Marker Oncology. 10(3):39-45, 1995.